Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1348

1.

Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons.

Asakawa K, Handa H, Kawakami K.

Nat Commun. 2020 Feb 21;11(1):1004. doi: 10.1038/s41467-020-14815-x.

PMID:
32081878
2.

Integrin α7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma.

Kobayashi N, Oda T, Takizawa M, Ishizaki T, Tsukamoto N, Yokohama A, Takei H, Saitoh T, Shimizu H, Honma K, Kimura-Masuda K, Kuroda Y, Ishihara R, Murakami Y, Murakami H, Handa H.

Cancers (Basel). 2020 Feb 5;12(2). pii: E363. doi: 10.3390/cancers12020363.

3.

Multipronged Approach to Combat Catheter-Associated Infections and Thrombosis by Combining Nitric Oxide and a Polyzwitterion: a 7 Day In Vivo Study in a Rabbit Model.

Singha P, Goudie MJ, Liu Q, Hopkins S, Brown N, Schmiedt CW, Locklin J, Handa H.

ACS Appl Mater Interfaces. 2020 Feb 17. doi: 10.1021/acsami.9b22442. [Epub ahead of print]

PMID:
32009376
4.

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.

Gotoh N, Minato Y, Saitoh T, Takahashi N, Kasamatsu T, Souma K, Oda T, Hoshino T, Sakura T, Ishizaki T, Shimizu H, Takizawa M, Yokohama A, Tsukamoto N, Handa H, Murakami H.

Eur J Haematol. 2020 Jan 31. doi: 10.1111/ejh.13393. [Epub ahead of print]

PMID:
32003046
5.

SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.

Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H.

Mol Cancer Res. 2020 Jan 23. doi: 10.1158/1541-7786.MCR-19-0391. [Epub ahead of print]

PMID:
31974290
6.

IgG4-related Disease with a Cardiac Mass.

Matsumura I, Mitsui T, Tahara K, Shimizu H, Yanagisawa K, Ishizaki T, Koiso H, Takizawa M, Yokohama A, Saitoh T, Hirato J, Murakami H, Handa H, Tsukamoto N.

Intern Med. 2020 Jan 17. doi: 10.2169/internalmedicine.4054-19. [Epub ahead of print]

7.

Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy.

Gao S, Zhang W, Wang R, Hopkins SP, Spagnoli JC, Racin M, Bai L, Li L, Jiang W, Yang X, Lee C, Nagata K, Howerth EW, Handa H, Xie J, Ma Q, Kumar A.

ACS Nano. 2020 Jan 21. doi: 10.1021/acsnano.9b05976. [Epub ahead of print]

PMID:
31939662
8.

Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.

Ogawa Y, Yanagisawa K, Naito C, Uchiumi H, Ishizaki T, Shimizu H, Gohda F, Ieko M, Ichinose A, Handa H.

Int J Hematol. 2020 Jan 14. doi: 10.1007/s12185-020-02823-y. [Epub ahead of print]

PMID:
31939075
9.

Biocompatibility of a polymer-coated membrane possessing a hydrophilic blood-contacting layer: Adsorption-related assessment.

Tagaya M, Okano S, Murataka T, Handa H, Ichikawa S, Takahashi S.

Int J Artif Organs. 2019 Dec 25:391398819895525. doi: 10.1177/0391398819895525. [Epub ahead of print]

PMID:
31875413
10.

RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen.

Hayakawa A, Sano R, Takahashi Y, Kubo R, Harada M, Omata M, Yokohama A, Handa H, Tsukada J, Takeshita H, Tsuneyama H, Ogasawara K, Kominato Y.

Transfusion. 2020 Jan;60(1):184-196. doi: 10.1111/trf.15628. Epub 2019 Dec 16.

PMID:
31840280
11.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N.

Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7.

PMID:
31701481
12.

The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma.

Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y.

Cancers (Basel). 2019 Nov 6;11(11). pii: E1738. doi: 10.3390/cancers11111738. Review.

13.

PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.

Kasamatsu T, Awata M, Ishihara R, Murakami Y, Gotoh N, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H.

Clin Exp Med. 2020 Feb;20(1):51-62. doi: 10.1007/s10238-019-00585-4. Epub 2019 Oct 16.

PMID:
31620907
14.

[Cereblon as a primary target of IMiDs].

Ito T, Handa H.

Rinsho Ketsueki. 2019;60(9):1013-1019. doi: 10.11406/rinketsu.60.1013. Review. Japanese.

PMID:
31597822
15.

p63 is a cereblon substrate involved in thalidomide teratogenicity.

Asatsuma-Okumura T, Ando H, De Simone M, Yamamoto J, Sato T, Shimizu N, Asakawa K, Yamaguchi Y, Ito T, Guerrini L, Handa H.

Nat Chem Biol. 2019 Nov;15(11):1077-1084. doi: 10.1038/s41589-019-0366-7. Epub 2019 Oct 7.

PMID:
31591562
16.

Successful Management of Acquired Factor V Inhibitor by Monitoring Factor V Activity, Antigen, and Inhibitor Values during Immunosuppressive Therapy.

Mihara M, Ogawa Y, Nagasaka M, Kobayashi N, Shimizu H, Shinozawa K, Fukutake K, Inoue M, Murakami M, Handa H.

Acta Haematol. 2019 Sep 27:1-5. doi: 10.1159/000502730. [Epub ahead of print]

PMID:
31563916
17.

[Thyroid storm and exacerbation of autoimmune hemolytic anemia following childbirth].

Sugisaki M, Ishizaki T, Iriuchishima H, Shimizu H, Yanagisawa K, Ogawa Y, Yokohama A, Saitoh T, Tsukamoto N, Handa H.

Rinsho Ketsueki. 2019;60(8):924-928. doi: 10.11406/rinketsu.60.924. Japanese.

PMID:
31484891
18.

Multifunctional S-Nitroso-N-acetylpenicillamine-Incorporated Medical-Grade Polymer with Selenium Interface for Biomedical Applications.

Mondal A, Douglass M, Hopkins SP, Singha P, Tran M, Handa H, Brisbois EJ.

ACS Appl Mater Interfaces. 2019 Sep 25;11(38):34652-34662. doi: 10.1021/acsami.9b10610. Epub 2019 Sep 10.

PMID:
31483604
19.

Heparin-Free Extracorporeal Life Support Using Tethered Liquid Perfluorocarbon: A Feasibility and Efficacy Study.

Roberts TR, Harea GT, Singha P, Sieck KN, Beely BM, Wendorff DS, Choi JH, Ande S, Handa H, Batchinsky AI.

ASAIO J. 2019 Aug 22. doi: 10.1097/MAT.0000000000001055. [Epub ahead of print]

PMID:
31453831
20.

Estradiol accelerates liver regeneration through estrogen receptor α.

Tsugawa Y, Natori M, Handa H, Imai T.

Clin Exp Gastroenterol. 2019 Jul 22;12:331-336. doi: 10.2147/CEG.S214196. eCollection 2019.

21.

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.

Hashimoto S, Furukawa S, Hashimoto A, Tsutaho A, Fukao A, Sakamura Y, Parajuli G, Onodera Y, Otsuka Y, Handa H, Oikawa T, Hata S, Nishikawa Y, Mizukami Y, Kodama Y, Murakami M, Fujiwara T, Hirano S, Sabe H.

Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17450-17459. doi: 10.1073/pnas.1901765116. Epub 2019 Aug 9.

22.

Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.

Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, Ohwada S, Okudaira N, Nakamura K, Sakajiri S.

Int J Hematol. 2019 Dec;110(6):654-664. doi: 10.1007/s12185-019-02709-8. Epub 2019 Jul 29.

PMID:
31359361
23.

Preeclampsia-Like Features and Partial Lactation Failure in Mice Lacking Cystathionine γ-Lyase-An Animal Model of Cystathioninuria.

Akahoshi N, Handa H, Takemoto R, Kamata S, Yoshida M, Onaka T, Ishii I.

Int J Mol Sci. 2019 Jul 17;20(14). pii: E3507. doi: 10.3390/ijms20143507.

24.

Versatile biomimetic medical device surface: hydrophobin coated, nitric oxide-releasing polymer for antimicrobial and hemocompatible applications.

Devine R, Singha P, Handa H.

Biomater Sci. 2019 Aug 1;7(8):3438-3449. doi: 10.1039/c9bm00469f. Epub 2019 Jul 3.

PMID:
31268063
25.

Molecular mechanisms of cereblon-based drugs.

Asatsuma-Okumura T, Ito T, Handa H.

Pharmacol Ther. 2019 Oct;202:132-139. doi: 10.1016/j.pharmthera.2019.06.004. Epub 2019 Jun 14. Review.

PMID:
31202702
26.

Correction to: Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).

Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K.

Int J Hematol. 2019 Jul;110(1):125-126. doi: 10.1007/s12185-019-02663-5.

PMID:
31119612
27.

Arginine induces IGF-1 secretion from the endoplasmic reticulum.

Tsugawa Y, Handa H, Imai T.

Biochem Biophys Res Commun. 2019 Jul 5;514(4):1128-1132. doi: 10.1016/j.bbrc.2019.05.044. Epub 2019 May 14.

PMID:
31101333
28.

Activin A: a novel urinary biomarker of renal impairment in multiple myeloma.

Iriuchishima H, Maeshima A, Takahashi S, Ishizaki T, Yokohama A, Tsukamoto N, Saitoh T, Murakami H, Handa H.

Biosci Rep. 2019 May 31;39(5). pii: BSR20190206. doi: 10.1042/BSR20190206. Print 2019 May 31.

29.

Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation.

Ando H, Sato T, Ito T, Yamamoto J, Sakamoto S, Nitta N, Asatsuma-Okumura T, Shimizu N, Mizushima R, Aoki I, Imai T, Yamaguchi Y, Berk AJ, Handa H.

iScience. 2019 May 31;15:95-108. doi: 10.1016/j.isci.2019.04.007. Epub 2019 Apr 9.

30.

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K.

Ann Hematol. 2019 Jul;98(7):1703-1711. doi: 10.1007/s00277-019-03702-1. Epub 2019 May 2.

PMID:
31049648
31.

Human telomerase reverse transcriptase expression in a CD34-positive hematopoietic progenitor of myelodysplastic syndrome and acute myelogenous leukemia.

Handa H, Nishimoto N, Inoue M, Yokohama A, Tsukamoto N, Saitoh T, Murakami H.

Hematol Oncol. 2019 Oct;37(4):520-522. doi: 10.1002/hon.2620. Epub 2019 May 30. No abstract available.

PMID:
30990910
32.

Magnetically Promoted Rapid Immunofluorescence Staining for Frozen Tissue Sections.

Onishi T, Matsuda S, Nakamura Y, Kuramoto J, Tsuruma A, Sakamoto S, Suzuki S, Fuchimoto D, Onishi A, Chikaki S, Kaneko M, Kuwahata A, Sekino M, Yasuno H, Hanyu N, Kurita T, Takei H, Sakatani T, Taruno K, Nakamura S, Hayashida T, Jinno H, Kusakabe M, Handa H, Kameyama K, Kitagawa Y.

J Histochem Cytochem. 2019 Aug;67(8):575-587. doi: 10.1369/0022155419841023. Epub 2019 Apr 8.

PMID:
30958084
33.

Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay.

Kamiya Y, Chou T, Murakami H, Handa H, Ozaki S, Shimazaki C, Fuchida SI, Okada J, Itoh J, Sugiyama S, Shimizu K.

Hematol Oncol. 2019 Aug;37(3):316-318. doi: 10.1002/hon.2611. Epub 2019 Apr 26. No abstract available.

PMID:
30938836
34.

Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia.

Tahara K, Koiso H, Osaki YH, Sekigami T, Yokohama A, Saitoh T, Tsukamoto N, Murakami H, Abe M, Handa H.

Acta Haematol. 2019;141(3):135-137. doi: 10.1159/000495741. Epub 2019 Feb 15. No abstract available.

35.

Zinc-oxide nanoparticles act catalytically and synergistically with nitric oxide donors to enhance antimicrobial efficacy.

Singha P, Workman CD, Pant J, Hopkins SP, Handa H.

J Biomed Mater Res A. 2019 Jul;107(7):1425-1433. doi: 10.1002/jbm.a.36657. Epub 2019 Mar 5.

PMID:
30737882
36.

[Recurrence of acquired factor V inhibitor after four years of remission].

Akashi N, Ogawa Y, Yanagisawa K, Osaki Y, Shimizu H, Ishizaki T, Inoue M, Murakami M, Souri M, Ichinose A, Handa H.

Rinsho Ketsueki. 2019;60(1):46-50. doi: 10.11406/rinketsu.60.46. Japanese.

PMID:
30726824
37.

Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).

Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K.

Int J Hematol. 2019 Apr;109(4):409-417. doi: 10.1007/s12185-019-02607-z. Epub 2019 Jan 31. Erratum in: Int J Hematol. 2019 Jul;110(1):125-126.

PMID:
30701467
38.

Correction to Tunable Nitric Oxide Release from S-Nitroso- N-acetylpenicillamine via Catalytic Copper Nanoparticles for Biomedical Applications.

Pant J, Goudie MJ, Hopkins SP, Brisbois EJ, Handa H.

ACS Appl Mater Interfaces. 2019 Jan 23;11(3):3627. doi: 10.1021/acsami.8b22363. Epub 2019 Jan 10. No abstract available.

PMID:
30629418
39.

Application of high-performance magnetic nanobeads to biological sensing devices.

Kabe Y, Sakamoto S, Hatakeyama M, Yamaguchi Y, Suematsu M, Itonaga M, Handa H.

Anal Bioanal Chem. 2019 Mar;411(9):1825-1837. doi: 10.1007/s00216-018-1548-y. Epub 2019 Jan 9. Review.

40.

Active Release of an Antimicrobial and Antiplatelet Agent from a Nonfouling Surface Modification.

Goudie MJ, Singha P, Hopkins SP, Brisbois EJ, Handa H.

ACS Appl Mater Interfaces. 2019 Jan 30;11(4):4523-4530. doi: 10.1021/acsami.8b16819. Epub 2019 Jan 16.

PMID:
30607929
41.

[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].

Iida S, Izumi T, Aotsuka N, Komeno T, Ishida T, Sunami K, Handa H, Berg D, Kase Y, Soeda J.

Rinsho Ketsueki. 2018;59(11):2399-2407. doi: 10.11406/rinketsu.59.2399. Japanese.

PMID:
30531133
42.

Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells.

Handa H, Hashimoto A, Hashimoto S, Sugino H, Oikawa T, Sabe H.

Cell Commun Signal. 2018 Dec 4;16(1):94. doi: 10.1186/s12964-018-0302-6.

43.

Antithrombotic properties of hemofilter coated with polymer having a hydrophilic blood-contacting layer.

Tagaya M, Hara K, Takahashi S, Nagoshi S, Handa H, Okano S, Murataka T.

Int J Artif Organs. 2019 Feb;42(2):88-94. doi: 10.1177/0391398818815480. Epub 2018 Nov 29.

44.

Prognostic impact of trisomy 21 in follicular lymphoma.

Mitsui T, Yokohama A, Koiso H, Saito A, Toyama K, Shimizu H, Ishizaki T, Irisawa H, Takizawa M, Saitoh T, Murayama K, Matsumoto M, Handa H, Hirato J, Kojima M, Murakami H, Tsukamoto N.

Br J Haematol. 2019 Feb;184(4):570-577. doi: 10.1111/bjh.15664. Epub 2018 Nov 12.

PMID:
30417943
45.

Clinical impact of serum soluble SLAMF7 in multiple myeloma.

Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H.

Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5.

46.

Two Types of Volatile Polyenes in the Brown Alga Sargassum thunbergii.

Lu SJ, Yosemoto S, Satomi D, Handa H, Akakabe Y.

J Oleo Sci. 2018;67(11):1463-1471. doi: 10.5650/jos.ess17276.

47.

Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.

Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, Noura M, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Shiba N, Yamato G, Handa H, Ono Y, Hiramoto N, Ishikawa T, Usuki K, Ishiyama K, Miyawaki S, Itonaga H, Miyazaki Y, Kawamura M, Yamaguchi H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Hayashi Y, Mano H, Miyano S, Kamikubo Y, Ogawa S, Adachi S.

Blood Adv. 2018 Nov 13;2(21):2879-2889. doi: 10.1182/bloodadvances.2018019398.

48.

Structural features of two major nucleolar organizer regions (NORs), Nor-B1 and Nor-B2, and chromosome-specific rRNA gene expression in wheat.

Handa H, Kanamori H, Tanaka T, Murata K, Kobayashi F, Robinson SJ, Koh CS, Pozniak CJ, Sharpe AG, Paux E; International Wheat Genome Sequencing Consortium, Wu J, Nasuda S.

Plant J. 2018 Dec;96(6):1148-1159. doi: 10.1111/tpj.14094. Epub 2018 Oct 27.

49.

Antibacterial 3D bone scaffolds for tissue engineering application.

Pant J, Sundaram J, Goudie MJ, Nguyen DT, Handa H.

J Biomed Mater Res B Appl Biomater. 2019 May;107(4):1068-1078. doi: 10.1002/jbm.b.34199. Epub 2018 Sep 19.

PMID:
30230685
50.

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy.

Tsukamoto N, Yokohama A, Higuchi T, Mitsui T, Koiso H, Takizawa M, Shimizu H, Ishizaki T, Matsumoto M, Toyama K, Sakura T, Ogura H, Saitoh T, Ishida F, Murakami H, Tsushima Y, Handa H.

Int J Hematol. 2019 Jan;109(1):91-97. doi: 10.1007/s12185-018-2526-z. Epub 2018 Sep 10.

PMID:
30203253

Supplemental Content

Support Center